Photo: Zero Creatives GmbH/GettyImages
SeqOne, a digital health company focused on genomic analysis tools for personalized medicine, announced it entered into a definitive agreement to acquire Congenica, a digital health company that provides software and other offerings for the analysis and interpretation of genomic data.
The acquisition connects SeqOne's AI-powered platform for next-generation sequencing analysis with Congenica's clinical decision support technology and clinical interpretation services.
The SeqOne platform is designed for molecular labs. It combines intuitive workflows with AI-powered bioinformatics to simplify genomic analysis and accelerate diagnostics.
SeqOne integrates lab systems and automates routine tasks from sample import to clinical reporting.
Congenica, a company spun out of the Wellcome Sanger Institute, provides automated analysis, diagnosis and treatment offerings to healthcare providers.
The company's products and services are consolidated on a single, scalable, automated analysis and diagnostic platform that covers inherited disease, somatic cancer, pharma insights and pathogen surveillance.
Additionally, Congenica is a clinical decision support partner for the National Health Service Genomic Medicine Service in the UK.
The companies said the acquisition will result in a "software pure player" that will serve more than 160 labs in 30 countries.
"By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services and deepening our presence in the UK market," Martin Dubuc, CEO of SeqOne, said in a statement.
THE LARGER TREND
In June, SeqOne announced a strategic collaboration with Agilent, aimed at enhancing the analysis of liquid biopsy data for oncology.
The partnership delivered two integrated tools, SomaMethyl and SomaLBx, optimized for Agilent's cutting-edge Avida Cancer panels and integrated into SeqOne's advanced bioinformatics platform to provide molecular labs with streamlined and robust data analysis capabilities.
In May, SeqOne announced a €20 million ($23 million) oversubscribed growth funding round. The funds were used to fuel the company's global expansion initiative.
In 2022, SeqOne Genomics announced a €20 million ($23 million) Series A funding round. Omnes, Merieux Equity Partners and the Software Club led the round.
Congenica completed a Series C funding round in 2020, raising $50 million (£39 million).
